“…The FDA approved the amplatzer vascular plug 1 and 2 for use in May 2004, and September 2007, respectively. Since that time, there have been numerous published reports describing their utility for vascular occlusion procedures in a variety of clinical settings, including the peripheral vasculature [3], pulmonary AVMs [11–13], venous collaterals [14], aorto‐pulmonary collaterals [15], coronary fistulae [16–18], patent ductus ateriosus [7, 19], modified Blalock‐Taussig shunts [20], Fontan fenestrations [21], ventriculo‐pulmonary connections [22], vena cava aneurysms [23], perivalvular leaks [24], and porto‐systemic connections [9, 25]. The majority of these reports are small series that describe the original plug 1 device, with few reports describing plug 2 [4–6].…”